-
-
-
-
-
-
-
Zymeworks completes acquisition of Theravance Biopharma
-
-
-
-
-
-
-
Zymeworks (ZYME) Reiterated at Buy by Stifel: 'Significantly Undervalued'
-
-
-
-
-
-
-
Zymeworks (ZYME) Reiterated at Buy by Stifel After AACR Presentation
-
-
-
-
-
-
-
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
-
-
-
-
-
-
-
Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets
-
-
-
-
-
-
-
Zymeworks (ZYME) Appoints Carlos E. Campoy to its Board
-
-
-
-
-
-
-
Zymeworks Adopts Limited-Duration Shareholder Rights Plan, Enabling All Shareholders to Realize Full Value of Company
-
1,200,839 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


